Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

We bring you the most exciting news from day one, including updates on automated insulin delivery, ways that technology can reduce hypoglycemia, and new physical activity recommendations Continue Reading »

Early trial results found that SGLT-2 inhibitor Farxiga is highly effective for preventing and treating kidney disease in people with or without type 2 diabetes Continue Reading »

JDRF's Mission Summit in La Jolla, California highlighted JDRF's efforts into multiple cures, plus more on complications Continue Reading »

Trulicity can now be prescribed to reduce the risk of stroke and heart attack in adults with type 2 diabetes and with heart disease or those who at risk for heart disease Continue Reading »

A new study shows that physical activity can add years to your life. Is this enough to motivate behavior change? Continue Reading »

Ozempic, a once weekly injectable GLP-1 agonist drug, is now approved to reduce the risk of heart attack and stroke. Rybelsus (a pill version of Ozempic) is confirmed to be safe for the heart Continue Reading »

Read on to learn about the research around GLP-1, SGLT-2, and combination therapy use in type 1 diabetes. Dr. Paresh Dandona is a Distinguished Professor and Chief of Endocrinology at the University of Buffalo, and Megan Johnson is a fellow on his team Continue Reading »

New guidelines from ADA and EASD focus on GLP-1 agonists and SGLT-2 inhibitors to improve heart and kidney health Continue Reading »

Pages